Hologic CE marks Adiana contraceptive
This article was originally published in Clinica
Hologic has CE marked its radiofrequency-based Adiana permanent contraception system for sale in Europe. The transcervical Adiana procedure uses a bi-polar radiofrequency energy catheter to remove cells lining a 1cm section of the inside of the fallopian tube. The catheter then delivers a soft polymer implant into the prepared section of the tube. The procedure is repeated on the other tube. The procedure is designed such that healthy tissue will grow into the matrix to create a complete blockage of each tube. The device is awaiting approval in the US, Canada and Australia, Bedford, Massachusetts-based Hologic said.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.